sevoflurane has been researched along with Pulmonary Fibrosis in 2 studies
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sevoflurane is identified as an effective candidate drug for acute lung injury (ALI) treatment, but its curing effects and detailed mechanisms have not been fully disclosed." | 8.12 | Sevoflurane reduces lipopolysaccharide-induced apoptosis and pulmonary fibrosis in the RAW264.7 cells and mice models to ameliorate acute lung injury by eliminating oxidative damages. ( Fu, Z; Wu, X; Zhang, J; Zhang, Y; Zheng, F, 2022) |
| "The aim of this study was to explore the influences of sevoflurane inhalation therapy on circulation function and pulmonary fibrosis in rats with pulmonary arterial hypertension (PAH) and the nuclear factor-κB (NF-κB) signaling pathway." | 7.91 | Sevoflurane improves circulatory function and pulmonary fibrosis in rats with pulmonary arterial hypertension through inhibiting NF-κB signaling pathway. ( Bai, X; Li, JL; Li, SM; Xi, J; Zhao, X, 2019) |
| "Sevoflurane is identified as an effective candidate drug for acute lung injury (ALI) treatment, but its curing effects and detailed mechanisms have not been fully disclosed." | 4.12 | Sevoflurane reduces lipopolysaccharide-induced apoptosis and pulmonary fibrosis in the RAW264.7 cells and mice models to ameliorate acute lung injury by eliminating oxidative damages. ( Fu, Z; Wu, X; Zhang, J; Zhang, Y; Zheng, F, 2022) |
| "The aim of this study was to explore the influences of sevoflurane inhalation therapy on circulation function and pulmonary fibrosis in rats with pulmonary arterial hypertension (PAH) and the nuclear factor-κB (NF-κB) signaling pathway." | 3.91 | Sevoflurane improves circulatory function and pulmonary fibrosis in rats with pulmonary arterial hypertension through inhibiting NF-κB signaling pathway. ( Bai, X; Li, JL; Li, SM; Xi, J; Zhao, X, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, F | 1 |
| Wu, X | 1 |
| Zhang, J | 1 |
| Fu, Z | 1 |
| Zhang, Y | 1 |
| Zhao, X | 1 |
| Bai, X | 1 |
| Li, JL | 1 |
| Li, SM | 1 |
| Xi, J | 1 |
2 other studies available for sevoflurane and Pulmonary Fibrosis
| Article | Year |
|---|---|
Sevoflurane reduces lipopolysaccharide-induced apoptosis and pulmonary fibrosis in the RAW264.7 cells and mice models to ameliorate acute lung injury by eliminating oxidative damages.
Topics: Acute Lung Injury; Animals; Antioxidants; Apoptosis; Kelch-Like ECH-Associated Protein 1; Lipopolysa | 2022 |
Sevoflurane improves circulatory function and pulmonary fibrosis in rats with pulmonary arterial hypertension through inhibiting NF-κB signaling pathway.
Topics: Administration, Inhalation; Animals; Disease Models, Animal; Down-Regulation; Humans; I-kappa B Prot | 2019 |